Open AccessHsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
Author(s) -
Jordi Codony-Servat,
Santiago Viteri,
Carles Codony-Servat,
Masaoki Ito,
J. Bracht,
Jordi Berenguer,
Imane Chaib,
Miguel Ángel Molina-Vila,
Niki Karachaliou,
Rafael Rosell
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.22
Subject(s) - osimertinib , viability assay , cancer research , cell culture , protein kinase b , heat shock protein , lung cancer , hsp90 inhibitor , cell growth , hsp90 , cell , phosphorylation , biology , medicine , chemistry , microbiology and biotechnology , biochemistry , receptor , epidermal growth factor receptor , pathology , genetics , gene , erlotinib
Osimertinib improve therapy for non-small cell lung cancer (NSCLC). However, invariable acquired resistance appears.